Contemporary strategies in the diagnosis and management of heart failure.

[1]  S. Dunlay,et al.  Preparedness planning before mechanical circulatory support: a "how-to" guide for palliative medicine clinicians. , 2014, Journal of pain and symptom management.

[2]  N. Shah,et al.  Impact of a Palliative Care Consult Service , 2014, The American journal of hospice & palliative care.

[3]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[4]  L. Wilkins.  A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study , 2013 .

[5]  M. Voskuil,et al.  Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial , 2013, European journal of heart failure.

[6]  Anju Bhardwaj,et al.  Soluble Concentrations of the Interleukin Receptor Family Member ST2 and &bgr;-Blocker Therapy in Chronic Heart Failure , 2013, Circulation. Heart failure.

[7]  J. Oh,et al.  Role of echocardiography in patients with intravascular hemolysis due to suspected continuous-flow LVAD thrombosis. , 2013, JACC. Cardiovascular imaging.

[8]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[9]  Harlan M. Krumholz,et al.  Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure , 2013, Circulation. Cardiovascular quality and outcomes.

[10]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[11]  G. Stevens,et al.  Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. , 2013, The Annals of thoracic surgery.

[12]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[13]  Akshay S. Desai,et al.  Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.

[14]  W. Kraus,et al.  Association between adrenergic receptor genotypes and beta‐blocker dose in heart failure patients: analysis from the HF‐ACTION DNA substudy , 2013, European journal of heart failure.

[15]  Robert L Kormos,et al.  Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  Mark A Hlatky,et al.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Circulation.

[17]  Yariv N. Marmor,et al.  Readmissions after implantation of axial flow left ventricular assist device. , 2013, Journal of the American College of Cardiology.

[18]  C. Yancy,et al.  Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. , 2013, Journal of the American College of Cardiology.

[19]  A. Moss,et al.  Cost‐Effectiveness of Cardiac Resynchronization Therapy in the MADIT‐CRT Trial , 2013, Journal of cardiovascular electrophysiology.

[20]  M. Link,et al.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2012, The Journal of thoracic and cardiovascular surgery.

[21]  L. Lund,et al.  Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. , 2012, JAMA.

[22]  Laura G. Qualls,et al.  Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. , 2012, JAMA.

[23]  M. Link,et al.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. , 2012, Circulation.

[24]  Randolph P. Martin,et al.  Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab , 2012, Circulation. Cardiovascular imaging.

[25]  Leora I. Horwitz,et al.  Contemporary evidence about hospital strategies for reducing 30-day readmissions: a national study. , 2012, Journal of the American College of Cardiology.

[26]  Akshay S. Desai,et al.  Rehospitalization for heart failure: predict or prevent? , 2012, Circulation.

[27]  Hanyu Ni,et al.  Prediction of Incident Heart Failure in General Practice: The Atherosclerosis Risk in Communities (ARIC) Study , 2012, Circulation. Heart failure.

[28]  V. Roger,et al.  Advance Directives in Community Patients With Heart Failure , 2012, Circulation. Cardiovascular quality and outcomes.

[29]  V. Jeevanandam.  Are we ready to implant left ventricular assist devices in "less sick" patients? , 2012, Seminars in thoracic and cardiovascular surgery.

[30]  C. Kramer,et al.  Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs , 2012, Journal of Nuclear Cardiology.

[31]  M. Slaughter,et al.  Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination Therapy , 2012, Circulation. Heart failure.

[32]  J. Oh,et al.  Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome , 2011, Circulation. Cardiovascular imaging.

[33]  R. Weinshilboum,et al.  The Impact of Pharmacogenomics on the Management of Cardiac Disease , 2011, Clinical pharmacology and therapeutics.

[34]  B. Bozkurt,et al.  Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). , 2011, Journal of cardiac failure.

[35]  R. Califf,et al.  The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. , 2011, Journal of cardiac failure.

[36]  S. Kushwaha,et al.  Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2011, Circulation. Heart failure.

[37]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[38]  Lesley H. Curtis,et al.  Do heart failure disease management programs make financial sense under a bundled payment system? , 2011, American heart journal.

[39]  R. Hershberger,et al.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[40]  Shunsuke Saito,et al.  Biventricular support using implantable continuous-flow ventricular assist devices. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  Richard Smith,et al.  Dartmouth Atlas of Health Care , 2011, BMJ : British Medical Journal.

[42]  Massimo Volpe,et al.  Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. , 2011, Archives of internal medicine.

[43]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[44]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[45]  J. Oh,et al.  Echocardiographic findings in stable outpatients with properly functioning HeartMate II left ventricular assist devices. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[46]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[47]  V. Roger,et al.  Lifetime Costs of Medical Care After Heart Failure Diagnosis , 2011, Circulation. Cardiovascular quality and outcomes.

[48]  J. Healey,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[49]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[50]  Dirk Westermann,et al.  Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. , 2010, Journal of cardiac failure.

[51]  W. Gibler,et al.  Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. , 2010, Circulation.

[52]  R. Carlson,et al.  Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? , 2010, Journal of the American College of Cardiology.

[53]  D. Kitzman,et al.  Exercise Training in Older Patients With Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial , 2010, Circulation. Heart failure.

[54]  M. Nieminen,et al.  Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. , 2010, European heart journal.

[55]  N. Uriel,et al.  Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. , 2010, Journal of the American College of Cardiology.

[56]  J. Rogers,et al.  Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. , 2010, The Annals of thoracic surgery.

[57]  W. Hundley,et al.  A Randomized Double-Blind Trial of Enalapril in Older Patients With Heart Failure and Preserved Ejection Fraction: Effects on Exercise Tolerance and Arterial Distensibility , 2010, Circulation. Heart failure.

[58]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[59]  C. O'connor,et al.  Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. , 2010, The American journal of cardiology.

[60]  F. Roila,et al.  Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[62]  A. V. Van Bakel,et al.  Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. , 2010, Journal of cardiac failure.

[63]  M. Mehra,et al.  Chronic heart failure: contemporary diagnosis and management. , 2010, Mayo Clinic proceedings.

[64]  D. Meier,et al.  Palliative Care in the Treatment of Advanced Heart Failure , 2009, Circulation.

[65]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[66]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[67]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[68]  B. Kozłowski.  [Commentary to the article: Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-38]. , 2009, Kardiologia polska.

[69]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[70]  Mark V. Williams,et al.  Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[71]  B. Griffith,et al.  Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. , 2009, Journal of the American College of Cardiology.

[72]  E. Benjamin,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[73]  Ana Morales,et al.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2009, Circulation. Heart failure.

[74]  M. Herregods,et al.  Prevalence of Left Ventricular Diastolic Dysfunction in a General Population , 2009, Circulation. Heart failure.

[75]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[76]  M. Gold,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[77]  D. Meier,et al.  Cost savings associated with US hospital palliative care consultation programs. , 2008, Archives of internal medicine.

[78]  H. Hillege,et al.  Anemia and mortality in heart failure patients a systematic review and meta-analysis. , 2008, Journal of the American College of Cardiology.

[79]  J. Killian,et al.  Anemia and heart failure: a community study. , 2008, The American journal of medicine.

[80]  Tamara B Harris,et al.  Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score , 2008, Circulation. Heart failure.

[81]  V. Roger,et al.  Death in Heart Failure: A Community Perspective , 2008, Circulation. Heart failure.

[82]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[83]  M. Costanzo,et al.  Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). , 2008, American heart journal.

[84]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2008, Journal of the American College of Cardiology.

[85]  P. Duarte,et al.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.

[86]  C. Pritchard,et al.  Monitoring left ventricular function in adults receiving anthracycline‐containing chemotherapy , 2007, European journal of heart failure.

[87]  J. Kors,et al.  Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community , 2007, Circulation.

[88]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[89]  Serguei V. S. Pakhomov,et al.  Systolic and diastolic heart failure in the community. , 2006, JAMA.

[90]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[91]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[92]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[93]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[94]  Albert Hofman,et al.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.

[95]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[96]  Daniel Levy,et al.  The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.

[97]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[98]  R. Bonow,et al.  Prevention and management of chronic heart failure in management of asymptomatic patients. , 2003, The American journal of cardiology.

[99]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[100]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[101]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[102]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[103]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[104]  Russell S. Kirby,et al.  The Dartmouth Atlas of Health Care , 1998 .

[105]  R. Doll,et al.  The Epidemiology of Cancer , 1980, Cancer.

[106]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[107]  M. Givertz,et al.  Mechanical Circulatory Support for Advanced Heart Failure: Patients and Technology in Evolution , 2012, Circulation.

[108]  E. Braunwald,et al.  Clinical Trial: Methods and Design Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network , 2012 .

[109]  S. Werns.  Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[110]  B. Kozłowski.  Summary of the article: Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. Engl J Med, 2011; 364: 797–805 , 2011 .

[111]  L. Hancock.  7. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med , 2011 .

[112]  T. Rywik.  [Summary of the article: Zannad F, McMurray JJV, Krum H et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21]. , 2011, Kardiologia polska.

[113]  Rene Quiroz,et al.  Long-term biventricular support with the heartware implantable continuous flow pump , 2010 .

[114]  F. Punzalan,et al.  Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. , 2004, The Cochrane database of systematic reviews.

[115]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[116]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[117]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[118]  N. Cook,et al.  Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association Endorsed by Heart Failure Society of America, American Association of Heart Failure Nurses, and Society for Medical Decision Making , 2022 .